BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
2 Steffen G, Sperle I, Leendertz SA, Sarma N, Beermann S, Thamm R, Bremer V, Zimmermann R, Dudareva S. The epidemiology of Hepatitis B, C and D in Germany: A scoping review. PLoS One 2020;15:e0229166. [PMID: 32150561 DOI: 10.1371/journal.pone.0229166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
4 Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6. [PMID: 30084409 DOI: 10.4103/ijmm.IJMM_17_381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Arboledas JCA, Guerrero IP, Rodríguez MJB, Martos ET, Pérez AB, León CC, Sierra Sánchez JF, Prieto MDL, Porcuna NC, Mochón MDO, Macías J, de la Iglesia Salgado A, Granger JR, Fernández MD, Lozano IG, Ramírez ER, Rivero A, Del Carmen Lozano Domínguez M, Viciana I, Montemayor JCG, García FG. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. Diagn Microbiol Infect Dis 2017;89:29-34. [PMID: 28669680 DOI: 10.1016/j.diagmicrobio.2017.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Pérez AB, Chueca N, García-deltoro M, Martínez-sapiña AM, Lara-pérez MM, García-bujalance S, Aldámiz-echevarría T, Vera-méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-arboledas JC, Poyato A, Téllez F, Rivero-juárez A, Merino D, Vivancos-gallego MJ, Rosales-zábal JM, García F, Ocete MD, Simón MÁ, Rincón P, Reus S, De la Iglesia A, García-arata I, Jiménez M, Jiménez F, Hernández-quero J, Galera C, Balghata MO, Primo J, Masiá M, Espinosa N, Delgado M, von-Wichmann MÁ, Collado A, Santos J, Mínguez C, Díaz-flores F, Fernández E, Bernal E, De Juan J, Antón JJ, Vélez M, Aguilera A, Navarro D, Arenas JI, Fernández C, Espinosa MD, Ríos MJ, Alonso R, Hidalgo C, Hernández R, Téllez MJ, Rodríguez FJ, Antequera P, Delgado C, Martín P, Crespo J, Becerril B, Pérez Ó, García-herola A, Montero J, Freyre C, Grau C. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Journal of Hepatology 2019;71:876-88. [DOI: 10.1016/j.jhep.2019.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Marascio N, Costantino A, Taffon S, Lo Presti A, Equestre M, Bruni R, Pisani G, Barreca GS, Quirino A, Trecarichi EM, Costa C, Mazzitelli M, Serapide F, Matera G, Torti C, Liberto MC, Ciccaglione AR. Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. J Clin Med 2021;10:1655. [PMID: 33924449 DOI: 10.3390/jcm10081655] [Reference Citation Analysis]
9 Pérez AB, Vrancken B, Chueca N, Aguilera A, Reina G, García-Del Toro M, Vera F, Von Wichman MA, Arenas JI, Téllez F, Pineda JA, Omar M, Bernal E, Rivero-Juárez A, Fernández-Fuertes E, de la Iglesia A, Pascasio JM, Lemey P, Garcia F, Cuypers L. Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. Euro Surveill 2019;24. [PMID: 30862327 DOI: 10.2807/1560-7917.ES.2019.24.9.1800227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
10 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
11 Sperle I, Steffen G, Leendertz SA, Sarma N, Beermann S, Thamm R, Simeonova Y, Cornberg M, Wedemeyer H, Bremer V, Zimmermann R, Dudareva S. Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. Front Public Health 2020;8:424. [PMID: 33014960 DOI: 10.3389/fpubh.2020.00424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Bar N, Levy S, Deutsch L, Leshno M, Rabinowich L, Younis F, Shibolet O, Katchman H. Hepatitis C related cognitive impairment: Impact of viral and host factors and response to therapy. J Viral Hepat 2021;28:870-7. [PMID: 33624351 DOI: 10.1111/jvh.13492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol 2018;68:597-600. [PMID: 28939133 DOI: 10.1016/j.jhep.2017.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
16 García Deltoro M, Ricart Olmos C. Hepatitis C virus infection and new treatment strategies. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37 Suppl 1:15-9. [PMID: 31138418 DOI: 10.1016/S0213-005X(19)30177-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Marascio N, Pavia G, Romeo I, Talarico C, Di Salvo S, Reale M, Marano V, Barreca GS, Fabiani F, Perrotti N, De Siena M, Giancotti F, Gravina T, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. J Med Virol 2018;90:1257-63. [PMID: 29575060 DOI: 10.1002/jmv.25073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
19 Navarro-de la Cruz D, Pérez-Castro S, Trigo-Daporta M, Aguilera-Guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:256-9. [PMID: 29759421 DOI: 10.1016/j.eimc.2018.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Palladino C, Sánchez-Carrillo M, Mate-Cano I, Vázquez-Morón S, Jimenez-Sousa MÁ, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep 2017;7:2892. [PMID: 28588311 DOI: 10.1038/s41598-017-02968-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cuomo G, Digaetano M, Menozzi M, Tagliazucchi S, Guaraldi G, Borghi V, Mussini C. Incidence of HCV infection amongst HIV positive men who had sex with men and prevalence data from patients followed at the Infectious Diseases Clinic of Modena, Italy. Dig Liver Dis 2018;50:1334-8. [PMID: 29929780 DOI: 10.1016/j.dld.2018.05.021] [Reference Citation Analysis]
22 Knops E, Heger E, Koenig C, Moebius U, Lübke N, Kaiser R, Di Cristanziano V, Hüsgen L, Kocyigit C, Rupp J, Sierra S. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection. Clinical Microbiology and Infection 2018;24:440-1. [DOI: 10.1016/j.cmi.2017.10.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
24 Isakov V, Hedskog C, Wertheim JO, Hostager RE, Parhy B, Schneider AB, Suri V, Mo H, Geivandova N, Morozov V, Bessonova E, Gankina N, Zhdanov K, Abdurakhmanov D, Svarovskaia E. Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. Int J Infect Dis 2021;113:36-42. [PMID: 34560266 DOI: 10.1016/j.ijid.2021.09.041] [Reference Citation Analysis]
25 Kyuregyan KK, Kichatova VS, Karlsen AA, Isaeva OV, Solonin SA, Petkov S, Nielsen M, Isaguliants MG, Mikhailov MI. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines 2020;8:E80. [PMID: 32272736 DOI: 10.3390/biomedicines8040080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Taherkhani R, Farshadpour F. Lurking epidemic of hepatitis C virus infection in Iran: A call to action. World J Hepatol 2017; 9(24): 1040-1042 [PMID: 28932350 DOI: 10.4254/wjh.v9.i24.1040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
27 Berg MG, Olivo A, Forberg K, Harris BJ, Yamaguchi J, Shirazi R, Gozlan Y, Sauleda S, Kaptue L, Rodgers MA, Mor O, Cloherty GA. Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses. PLoS One 2020;15:e0236046. [PMID: 32678844 DOI: 10.1371/journal.pone.0236046] [Reference Citation Analysis]
28 Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging 2018;35:843-57. [PMID: 30084012 DOI: 10.1007/s40266-018-0572-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
29 Dietz J, Kalinina OV, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group. Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat 2020;27:974-86. [DOI: 10.1111/jvh.13322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One 2017;12:e0175525. [PMID: 28406947 DOI: 10.1371/journal.pone.0175525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
31 Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35. [PMID: 32141821 DOI: 10.5152/tjg.2020.18798] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019;14:e0221231. [PMID: 31469856 DOI: 10.1371/journal.pone.0221231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Marascio N, Mazzitelli M, Scarlata GG, Giancotti A, Barreca GS, Lamberti AG, Divenuto F, Costa C, Trecarichi EM, Matera G, Liberto MC, Torti C. HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018). TOMICROJ 2020;14:84-90. [DOI: 10.2174/1874285802014010084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sanchez Antolin G, Testillano M, Pascasio JM, Narvaez Rodriguez I, Prieto M, Otero A, Herrero JI, Londoño M, Fernandez Vazquez I, Castells L; Spanish Society of Liver Transplantation Study Group Collaborating Group. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplant Proc 2016;48:3013-6. [PMID: 27932134 DOI: 10.1016/j.transproceed.2016.08.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Walker A, Bergmann M, Camdereli J, Kaiser R, Lübke N, Timm J. A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing. Journal of Clinical Virology 2017;91:42-8. [DOI: 10.1016/j.jcv.2017.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
37 Palladino C, Esteban-Cartelle B, Mate-Cano I, Sánchez-Carrillo M, Resino S, Briz V. Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. Enferm Infecc Microbiol Clin (Engl Ed) 2018;36:262-7. [PMID: 28521955 DOI: 10.1016/j.eimc.2017.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Jafri SM, Gordon SC. Epidemiology of Hepatitis C. Clin Liver Dis (Hoboken) 2018;12:140-2. [PMID: 30988931 DOI: 10.1002/cld.783] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64. [PMID: 30265418 DOI: 10.1111/jvh.13008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
40 Walker A, Ennker KS, Kaiser R, Lübke N, Timm J. A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing. J Clin Virol 2019;113:8-13. [PMID: 30771598 DOI: 10.1016/j.jcv.2019.01.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol 2017;89:1304-8. [PMID: 28079256 DOI: 10.1002/jmv.24766] [Reference Citation Analysis]
42 Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells 2019;8:E666. [PMID: 31269695 DOI: 10.3390/cells8070666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 Rayan Da'as S, Azzeh M. Subgenotyping and genetic variability of hepatitis C virus in Palestine. PLoS One 2019;14:e0222799. [PMID: 31589628 DOI: 10.1371/journal.pone.0222799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Van den Borre C, Schuermans W, Van Vlierberghe H, Geerts A, Verhelst X, Padalko E. Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1. J Clin Virol 2016;83:54-5. [PMID: 27591556 DOI: 10.1016/j.jcv.2016.08.291] [Reference Citation Analysis]